 |
|
Nitrate Therapy and the Development of Tolerance
Udho Thadani, MBBS, MRCP, FRCPC
Arch Fam Med. 1993;2(8):880-885.
References
Article references have been provided for searching and linking. Additional reference information may be available in the article PDF.
| |
1. Thadani U. Current status of nitrates in angina pectoris. Med Concept Cardiovasc Dis. 1987;56:49-54.
2. Thadani U, Whitsett T, Hamilton SF. Nitrate therapy for myocardial ischemia syndrome: current perspectives including tolerance. Curr Probl Cardiol. 1988;13:731-784.
3. Abrams A. Newer concepts on using nitrates in angina pectoris. Contemp Int Med. 1991;3:92-103.
4. Thadani U, Fung HL, Darke AC, Parker JO. Oral isosorbide dinitrate in angina pectoris: comparison of duration of action and dose-response relation during acute and sustained therapy. Am J Cardiol. 1982;49:411-419.
PUBMED
5. Parker JO, Farrell B, Lahey KA, Moe G. Effect of intervals between doses on the development of tolerance to isosorbide dinitrate. N Engl J Med. 1987;316:1440-1444.
ABSTRACT
6. Parker JO, VanKoughnett K, Farrell B. Comparison of buccal nitroglycerin and oral isosorbide dinitrate for nitrate tolerance in stable angina pectoris. Am J Cardiol. 1985;56:724-728.
PUBMED
7. Steering Committee, Transdermal Cooperative Study. Acute and chronic antianginal efficacy of continuous twenty-four-hour application of transdermal nitroglycerin. Am J Cardiol. 1991;68:1263-1279.
PUBMED
8. Silber S. Clinical relevance of nitrate tolerance. In: Cohn JN, Rittinghausen R, eds. Mononitrates. New York, NY: Springer Verlag NY Inc; 1985:130-145. 9. Schelling JL, Lasagna L. A study of crosstolerance to circulatory effects of organic nitrates. Clin Pharmacol Ther. 1967;3:256-260.
10. Thadani U, Manyari D, Parker JV, Fung HL. Tolerance to the circulatory effects of oral isosorbide dinitrate: rate of development and crosstolerance to glyceryl trinitrate. Circulation. 1980;61:526-535.
FREE FULL TEXT
11. Danahy DT, Aronow WS. Hemodynamics and antianginal effects of high dose oral isosorbide dinitrate after chronic use. Circulation. 1977;56:205-212.
FREE FULL TEXT
12. Lee G, Mason DT, Amsterdam EA, Miller RA, DeMaria AN. Antianginal efficacy of oral therapy with isosorbide dinitrate capsules: prolonged benefits shown by exercise testing in patients with ischemic heart disease. Chest. 1978;73:327-332.
PUBMED
13. Elkayam U. Tolerance to organic nitrates: evidence, mechanisms, clinical relevance, and strategies for prevention. Ann Intern Med. 1991;114:667-677.
FREE FULL TEXT
14. Thadani U. Role of nitrates in angina pectoris. Am J Cardiol. 1992;70:43-53.
15. Scardi S, Camerini F, Pandullo G, Pollavini G, the Collaborative Nitro Group. Efficacy of continuous and intermittent transdermal treatment with nitroglycerin in effort angina pectoris: a multicenter study. Int J Cardiol. 1991;32:241-248.
PUBMED
16. Colditz GA, Halvorsen KT, Goldhaeber SZ. Randomized clinical trials of transdermal nitroglycerin systems for the treatment of angina: a meta analysis. Am Heart J. 1988;116:174-180.
PUBMED
17. Klemsdal TO, Gjesdal K. The effect of transdermal nitroglycerin on exercise tolerance in relation to patch application time: a meta analysis. Cardiovasc Drugs Ther. 1992;6:641-649.
PUBMED
18. James MA, Papouchado M, Jones V. Attenuation of nitrate effect during an intermittent treatment regimen and the time course of nitrate tolerance. Eur Heart J. 1991;12:1266-1272.
FREE FULL TEXT
19. Thadani U. Factors influencing tolerance in nitrate therapy: a review. In: Julian DG, Rittinghausen R, Uberbacher HJ, eds. Mononitrates II. New York, NY: Springer Verlag NY Inc; 1987:82-98. 20. Abrams J. Nitrate tolerance in angina pectoris. In: Cohn JN, Rittinghausen R, eds. Mononitrates. New York, NY: Springer Verlag NY Inc; 1985:154-170. 21. Ohlmeier H, Mertens HM, Mannebach H, Gleichmann U. Tolerance and rebound phenomena in nitrate therapy. In: Cohn JN, Rittinghausen R, eds. Mononitrates. New York, NY: Springer Verlag NY Inc; 1985:107-123. 22. Parker JO, Van Koughnett KA, Fung HL. Transdermal isosorbide dinitrate in angina pectoris: effect of acute and sustained therapy. Am J Cardiol. 1984;54:8-13.
PUBMED
23. Fox KM, Dargie HJ, Deanfield J, Maseri A, the Transdermal Nitrate Investigators. Avoidance of tolerance and lack of rebound with intermittent dose titrated transdermal glyceryl trinitrate. Br Heart J. 1991;66:151-155.
FREE FULL TEXT
24. DeMots H, Glasser SP. Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina. J Am Coll Cardiol. 1989;13:786-793.
ABSTRACT
25. Friedman RG, the Isorbide Mononitrate Study Group. Comparative clinical trial of isosorbide mononitrate and isosorbide dinitrate in patients with stable angina. J Invas Cardiol. 1992;4:319-329.
26. Thadani U, Friedman R, Jones JP, Heberton RK, Pierson WC. Nitrate tolerance: eccentric versus concentric twice daily therapy with isosorbide5-mononitrate in angina pectoris. Circulation. 1989;(suppl_ll):216. Abstract. 27. Thadani U, Bittar N. Effects of 8:00 am and 2 pm doses of isosorbide-5-mononitrate during twice daily therapy in stable angina pectoris. Am J Cardiol. 1992;70:286-292.
PUBMED
28. Needleman P, Johnson EM. Mechanism of tolerance development to organic nitrates. J Pharmacol Exp Ther. 1973;184:709-715.
FREE FULL TEXT
29. Armstrong PW, Moffat JA. Tolerance to organic nitrates. Am J Med. 1983;74(suppl):73-84.
PUBMED
30. Packer M, Lee WH, Kessler PD, Gottlieb SS, Medina N, Yushak M. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med. 1987;317:799-804.
ABSTRACT
31. Dupuis J, Lalonde G, Lemieux R, Rouleau JL. Tolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased intravascular volume, neurohumoral activation and lack of prevention with N-acetylcysteine. J Am Coll Cardiol. 1990;16:923-931.
ABSTRACT
32. Lis Y, Bennett D, Lambert G, Robson D. A preliminary double-blind study of intravenous nitroglycerin in acute myocardial infarction. Intensive Care Med. 1984;10:179-184.
PUBMED
33. Chung SJ, Fung HL. Relationship between nitroglycerin induced vascular relaxation and nitric oxide production: problems with inhibitors and tolerance development. Biochem Pharmacol. 1993;45:157-163.
PUBMED
34. Ghio S, de Servi S, Perotti S, Eleuteri E, Montemartini C, Specchia G. Different susceptibility to the development of nitroglycerin tolerance in the arterial and venous circulation in humans: effects of N-acetylcysteine administration. Circulation. 1992;86:798-802.
FREE FULL TEXT
35. Fung H-L, Sutton SC, Kamiya A. Vascular pharmacokinetics of nitrates. In: Cohn JN, Rittinghausen R, eds. Mononitrates. New York, NY: Springer Verlag NY Inc; 1985:67-72. 36. Jansen W, Osterpey A, Tachert M, et al. 5-lsosorbidmononitrat unter Ruhe- und Belastungsbedingungen bei koronarer Herzkrankheit. Dtsch Med Wochenschr. 1982;107:1499.
PUBMED
37. Seabra-Gomes R, Alelxo AM, Adao M, et al. Comparison of the effects of a controlled-release formulation of isosorbide-5-mononitrate and conventional isosorbide dinitrate on exercise performance in men with stable angina pectoris. Am J Cardiol. 1990;65:1308-1312.
PUBMED
38. Reichek N, Priest C, Zimrin D, Chancler T, St. John Sutton M. Antianginal effects of nitroglycerin patches. Am J Cardiol. 1984;54:1-7.
PUBMED
39. Zimrin D, Reichek N, Bogin KT, et al. Antianginal effects of intravenous nitroglycerin over 24 hours. Circulation. 1988;77:1376-1384.
FREE FULL TEXT
40. Silber S, Vogler AC, Spiegelsberger F, Thelson K. Once daily 120 mg isosorbide dinitrate in slow release form: placebo controlled evaluation of its duration of action. Circulation. 1986;74(suppl II):136. Abstract.
41. Thadani U, Hamilton SF, Olson EG, et al. Duration of effects and tolerance of slow release isosorbide-5-mononitrate for angina pectoris. Am J Cardiol. 1987;59:756-762.
PUBMED
42. Thadani U, Hamilton SF, Olson E, et al. Transdermal nitroglycerin patches in angina pectoris: dose titration, duration of effects, and rapid tolerance. Ann Intern Med. 1986;105:485-492.
FREE FULL TEXT
43. Bassan MM. The daylong pattern of the antianginal effects of long-term three times daily administered isosorbide dinitrate. J Am Coll Cardiol. 1990;16:936-940.
ABSTRACT
44. Waters DD, Juneau M, Gossard, Choquette MD, Brien M. Limited usefulness of intermittent nitroglycerin patches in stable angina. J Am Coll Cardiol. 1989;13:421-425.
ABSTRACT
45. Ferrantini M, Pirelli S, Merlini P, Silva P, Pollavini G. Intermittent transdermal nitroglycerin monotherapy in stable exercise induced angina: a comparison with a continuous schedule. Eur Heart J. 1989;10:998-1002.
FREE FULL TEXT
46. Thadani U. Nitrate tolerance: how to prevent it or minimize its effect? Postgrad Med. 1992;91:307-318.
PUBMED
47. Jones JP, the lsosorbide-5-Mononitrate Study Cooperative. Dose response of isosorbide-5mononitrate in patients with angina pectoris. In: Julian DG, Rittinghausen R, Uberbacher HJ, eds. Mononitrates II. New York, NY: Springer Verlag NY Inc; 1987:61-68. 48. Thadani U, the IS-5-MN Study Group. Isosorbide5-mononitrate (IS-5-MN) in angina pectoris: efficacy of am and pm doses, lack of tolerance and zero hour effect during eccentric BID therapy. Circulation. 1991;84:730. Abstract.
49. Parker JO, Farrell LLB, Lahey KA, Rose BP. Nitrate tolerance: the lack of effect of N-acetylcysteine. Circulation. 1987;76:572-576.
FREE FULL TEXT
|
